Phase II Trial of Reduced-Intensity Fludarabine, Melphalan 70 Mg/m2, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant

Haploidentical (haplo) hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) was initially developed with fludarabine/cyclophosphamide/total body irradiation (TBI) conditioning, resulting in low toxicity but high rates of relapse. We hypothesized that substituting melphalan 70 mg/m2 for cyclophosphamide in the conditioning regimen could successfully reduce the risk of relapse without substantially increasing non-relapse mortality (NRM), thus improving disease-free survival (DFS) in patients unfit for myeloablative conditioning.

https://www.astctjournal.org/article/S2666-6367(23)01828-6/fulltext?rss=yes

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Hany Elmariah, Jongphil Kim, Elizabeth DiMaggio, Rebecca Gonzalez, Jongphil Kim, Jongphil Kim, Asmita Mishra, Rawan G Faramand, Lia Elena Perez, Aleksandr Lazaryan, Farhad Khimani, Hien Liu, Leonel Ochoa, Dr. Michael L. Nieder, Nicholas Figura, Timothy Ro Tags: 65 Source Type: research